Clinical Studies

It’s EuroPCR week, so cardiothoracic companies are timing their press announcements to coincide with the event. Californian company Elixir Medical’s fully bioabsorbable drug eluting coronary scaffold has been the subject of what looks like a very promising clinical study presented during the event.

Zephyr Endobronchial Valve (EBV) therapy guided by Chartis Assessment is effective in a broad range of patients according to a new study, published in the European Respiratory Journal and flaunted by pulmonology company Pulmonx.

Edwards Lifesciences is trumpeting the newly released results from a study of its Intuity Valve System, which suggests small incision surgery is fast, safe and clinically effective.

GI Dynamics Inc is no doubt delighted to see its product featuring at the Obesity and metabolic Disorders congress, especially as a presentation suggests its Endobarrier® device can be used a second time on the same patient without problems.

Another fascinating study shows a positive effect of stem cell infusion in post-infarct patients when compared with standard of care control group.

Israeli company Brainsway put its money where its mouth is when it undertook a major clinical study into the effect of its therapy on unresponsive depression sufferers. The results suggest it paid off as significant improvements were noted in the treatment group.

Turmeric is supposed to be good for us, but now its beginning to look like a wonder spice as researchers suggest it can reduce post cardiac surgical incidence of heart attack in a placebo study.

When is a published paper a thinly disguised marketing study? One man clearly has a view.

Medtronic’s clinical ambitions are laid bare at CX34 as it announces the imminent start of its 1500 patient evaluation of peripheral artery treatment using its IN.PACT Drug-eluting balloon.

Aussie regenerative medicine outfit Mesoblast Ltd is making great progress with its US phase 2 study into the effect of stem cell injections in mitigating low back pain.

More from CX34 as Medtronic’s Endurant AAA Stent Graft 2 year data gets a positive airing.

Stenting still has a way to go if it’s to persuade the vascular community it’s a routine alternative to Carotid Endarterectomy.

The first patient has been implanted with St.Jude’s Accent MRI® Pacemaker in a study to determine whether the device will be compatible with full body MRI scans once in situ.

Endovascular aneurysm repair looks like it can be supported in ruptured aneurysms, but other factors need to be taken into account as real-world studies from two Swiss Centres don’t harmonise.

Bioabsorbable stents are back in the news with the publication of ten year data from Japan claiming safety at ten years in a 50 patient study.

Study into Cancer risk in the first seven years after Metal-on-Metal Hip Replacement compared with other bearings and general population: linkage study between the National Joint Registry of England and Wales and hospital episode statistics.